EW’s stock price forecast this week factors in resilience in cardiovascular product sales, with consensus EPS revisions moving +3% higher. This uptick aligns with broader healthcare sector strength reflected in the S&P Healthcare Index. Of the total revenue, $87.4 million came from Japan during the last fiscal quarter, accounting for 6.3%. This represented a surprise of -29.06% as analysts had expected the region to contribute $123.2 million to the total revenue. In comparison, the region contributed $110.8 million, or 6.9%, and $117.9 million, or 7.7%, to total revenue in the previous and year-ago quarters, respectively. We have seen 574 institutional investors add shares of $EW stock to their portfolio, and 640 decrease their positions in their most recent quarter. The latest EW stock price forecast points to a moderate upside, with analysts eyeing a target range of $92–$97 over the next quarter, driven by stable revenue growth and strong demand in the medical devices segment. Trading volume has shown consistent institutional interest, which often signals a healthy technical setup.